Bristol-Myers Squibb Co (NYSE:BMY) and Infinity Pharmaceuticals Inc. (NASDAQ:INFI) have recently entered into an agreement to commence a collaborative clinical trial evaluating the former’s Opdivo in combination with the latter’s IPI-549 for the treatment of patients with advanced solid tumors. Opdivo and IPI-549 Opdivo has been specifically developed to deal with immunosuppression. It is the […]